Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2015
Accounting Basis: International Financial Reporting Standards (IFRS)
Key Strategic Event: The year was defined by the completion of a major transaction with Novartis on March 2, 2015. GSK acquired Novartis's Vaccines business and formed a joint venture for Consumer Healthcare products, while divesting its Oncology business to Novartis. This restructuring aimed to create a more balanced portfolio across Pharmaceuticals, Vaccines, and Consumer Healthcare.
Key Financial Metrics
| Metric | 2015 (£m) | 2014 (£m) | Change |
|---|---|---|---|
| Turnover | 23,923 | 23,006 | +6% (CER) |
| Operating Profit (Total) | 10,322 | 3,597 | >100% |
| Operating Profit (Core) | 5,729 | 6,594 | -9% (CER) |
| Profit Before Taxation | 10,526 | 2,968 | >100% |
| Profit After Taxation | 8,372 | 2,831 | >100% |
| Earnings Per Share (Total) | 174.3p | 57.3p | >100% |
| Earnings Per Share (Core) | 75.7p | 95.4p | -15% (CER) |
| Free Cash Flow | 2.5 billion (Adjusted) | 3.9 billion (Adjusted) | Decline |
| Net Debt Reduction | 3.7 billion | N/A | N/A |
Note: CER = Constant Exchange Rate. Core results exclude amortization, impairment, major restructuring, legal charges, and acquisition accounting adjustments.
Material Changes vs. Prior Period
- Portfolio Restructuring: The divestment of the high-margin Oncology business and the acquisition of lower-margin Vaccines and Consumer Healthcare businesses from Novartis significantly altered the cost structure and margin profile. Core operating margin declined 4.1 percentage points to 23.9%.
- Revenue Drivers: Total turnover grew 6% (CER). This growth was driven by the new Vaccines (+19%) and Consumer Healthcare (+44%) segments, which offset a 7% decline in the Pharmaceuticals segment (primarily due to the Oncology divestment and a 13% decline in Seretide/Advair sales).
- Profitability Volatility: Total operating profit surged due to a £9.2 billion profit on the disposal of the Oncology business. However, underlying core operating profit fell 9% (CER) due to the transition costs and the lower margin mix of the new portfolio.
- Legal and Restructuring Costs: Major restructuring charges were £1.89 billion (up from £750 million in 2014) as GSK accelerated integration programs. Legal charges were £221 million (down from £548 million in 2014, which included a £301 million fine in China).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Dividend Policy: The Board declared an ordinary dividend of 80 pence per share for 2015 and expects to maintain this level for 2016 and 2017. A special dividend of 20 pence per share was declared, to be paid in April 2016 from disposal proceeds.
- Strategic Priorities: Management is prioritizing cash flow generation to support the dividend and fund restructuring. The goal is to transition away from reliance on Seretide/Advair toward new products in Pharmaceuticals, Vaccines, and Consumer Healthcare.
- Cost Savings: The restructuring and integration program delivered £1.6 billion in annual savings by year-end and is on track to deliver £3 billion in total annual savings by the end of 2017.
- New Product Growth: Sales of new Pharmaceutical and Vaccine products reached £1.99 billion, with management now expecting these products to generate £6 billion in annual revenue by 2018 (two years ahead of the previous 2020 target).
Risks and Contingencies
- Patent Expirations: Continued pressure from generic competition, particularly for Seretide/Advair (US patent on the device expires August 2016) and Avodart (US patent expired October 2015).
- Legal Proceedings: Ongoing exposure to product liability, patent, and antitrust litigation. Significant unresolved disputes are detailed in the Annual Report (Note 45).
- Regulatory and Tax: Risks related to changing regulatory regimes, patient safety, and international tax reform (e.g., OECD BEPS project) which could impact the effective tax rate.
- Supply Chain: Risks regarding product quality, data integrity, and reliance on third-party suppliers for active pharmaceutical ingredients.
Investor Verification Checklist
- Core vs. Total Earnings: Verify the distinction between Total EPS (174.3p) and Core EPS (75.7p) to understand the impact of the one-time Oncology disposal profit on reported earnings.
- Debt and Liquidity: Confirm the reduction of net debt by £3.7 billion and the retention of disposal proceeds to fund the transition and maintain credit ratings.
- Restructuring Progress: Monitor the delivery of the targeted £3 billion in annual savings by 2017 and the associated cash outflows (£1.1 billion paid in 2015).
- Patent Cliff Exposure: Assess the timeline and financial impact of the US patent expiration for the Advair Diskus device in August 2016.
- Dividend Sustainability: Evaluate the ability to maintain the 80 pence ordinary dividend given the current cash flow generation is below the dividend payout level during the transition period.